Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Danicopan

FDA-approved product (tablet, oral), marketed as Voydeya.

Registered studies
30
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Danicopan
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acquired paroxysmal nocturnal hemoglobinuria
  • Hemoglobinuria, Paroxysmal
  • Hemolysis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Complement inhibitors
FDA pharmacologic class
Complement Factor D Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA68.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

30registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Danicopan in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

-9.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Danicopan with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Danicopan PMS in Korea

    NCT07457151 · start 2026-04-10

    Registered record
    Registry ID
    NCT07457151
    Conditions
    Paroxysmal Nocturnal Hemoglobinuria
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2026-04-10
    Completion
    2028-06-27
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParoxysmal Nocturnal Hemoglobinuria
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data

    NCT07413250 · start 2026-01-14

    Registered record
    Registry ID
    NCT07413250
    Conditions
    Paroxysmal Nocturnal Hemoglobinuria; PNH
    Interventions
    Danicopan; Soliris/Ultomiris
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2026-01-14
    Completion
    2030-01-15
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParoxysmal Nocturnal Hemoglobinuria; PNH
    InterventionDanicopan; Soliris/Ultomiris
    PhaseNot recorded
    Registry statusActive not recruiting

  • Long-term Safety of Danicopan: IPIG Registry-based Cohort Study

    NCT07413679 · start 2025-08-18

    Registered record
    Registry ID
    NCT07413679
    Conditions
    Paroxysmal Nocturnal Hemoglobinuria; PNH
    Interventions
    Danicopan
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2025-08-18
    Completion
    2029-07-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParoxysmal Nocturnal Hemoglobinuria; PNH
    InterventionDanicopan
    PhaseNot recorded
    Registry statusActive not recruiting

  • Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis

    NCT06449001 · start 2025-08-11

    Registered record
    Registry ID
    NCT06449001
    Conditions
    Paroxysmal Nocturnal Hemoglobinuria; PNH; Extravascular Hemolysis
    Interventions
    Danicopan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-08-11
    Completion
    2028-03-10
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParoxysmal Nocturnal Hemoglobinuria; PNH; Extravascular Hemolysis
    InterventionDanicopan
    PhasePhase 3
    Registry statusRecruiting

  • A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

    NCT05389449 · start 2022-10-28

    Registered record
    Registry ID
    NCT05389449
    Conditions
    Paroxysmal Nocturnal Hemoglobinuria
    Interventions
    Danicopan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2022-10-28
    Completion
    2026-08-24
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParoxysmal Nocturnal Hemoglobinuria
    InterventionDanicopan
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

    NCT05019521 · start 2021-08-23

    Registered record
    Registry ID
    NCT05019521
    Conditions
    Geographic Atrophy
    Interventions
    Danicopan; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2021-08-23
    Completion
    2025-01-21
    Enrolment
    365

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGeographic Atrophy
    InterventionDanicopan; Placebo
    PhasePhase 2
    Registry statusTerminated

  • ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19

    NCT04988035 · start 2021-08-03

    Registered record
    Registry ID
    NCT04988035
    Conditions
    COVID-19
    Interventions
    Danicopan; Placebo; Remdesivir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-08-03
    Completion
    2022-04-23
    Enrolment
    201

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionDanicopan; Placebo; Remdesivir
    PhasePhase 2
    Registry statusCompleted

  • Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)

    NCT04469465 · start 2020-12-16

    Registered record
    Registry ID
    NCT04469465
    Conditions
    Paroxysmal Nocturnal Hemoglobinuria
    Interventions
    Danicopan; Placebo; C5 Inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-12-16
    Completion
    2024-01-16
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParoxysmal Nocturnal Hemoglobinuria
    InterventionDanicopan; Placebo; C5 Inhibitor
    PhasePhase 3
    Registry statusCompleted

  • Study of the Metabolism of Danicopan in Healthy Adults

    NCT04609696 · start 2020-10-20

    Registered record
    Registry ID
    NCT04609696
    Conditions
    Healthy
    Interventions
    Danicopan: Powder-In-Capsule 1; Danicopan: Powder-In-Capsule 2; Danicopan: Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-10-20
    Completion
    2020-12-07
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDanicopan: Powder-In-Capsule 1; Danicopan: Powder-In-Capsule 2; Danicopan: Tablet
    PhasePhase 1
    Registry statusCompleted

  • Study of Danicopan in Participants of Japanese Descent

    NCT04451434 · start 2020-08-17

    Registered record
    Registry ID
    NCT04451434
    Conditions
    Healthy
    Interventions
    Danicopan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-08-17
    Completion
    2020-09-28
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDanicopan
    PhasePhase 1
    Registry statusCompleted

  • A Study of the Effects of Food and Age on Danicopan

    NCT04551599 · start 2020-02-21

    Registered record
    Registry ID
    NCT04551599
    Conditions
    Healthy
    Interventions
    Danicopan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-02-21
    Completion
    2021-02-03
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDanicopan
    PhasePhase 1
    Registry statusCompleted

  • Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy

    NCT04170023 · start 2019-12-16

    Registered record
    Registry ID
    NCT04170023
    Conditions
    Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Interventions
    ALXN2050
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-12-16
    Completion
    2024-03-20
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParoxysmal Nocturnal Hemoglobinuria (PNH)
    InterventionALXN2050
    PhasePhase 2
    Registry statusTerminated

  • A Drug Interaction Study of Danicopan

    NCT04709094 · start 2019-07-28

    Registered record
    Registry ID
    NCT04709094
    Conditions
    Healthy
    Interventions
    Danicopan; Warfarin; Bupropion; Ethinyl Estradiol/Norethindrone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-07-28
    Completion
    2020-04-17
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDanicopan; Warfarin; Bupropion; Ethinyl Estradiol/Norethindrone
    PhasePhase 1
    Registry statusCompleted

  • A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults

    NCT05109390 · start 2018-07-27

    Registered record
    Registry ID
    NCT05109390
    Conditions
    Healthy
    Interventions
    Danicopan; Cyclosporine; Tacrolimus; Calcium Carbonate; Aluminum/Magnesium Hydroxide/Simethicone; Omeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-07-27
    Completion
    2018-10-17
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDanicopan; Cyclosporine; Tacrolimus; Calcium Carbonate +2 more
    PhasePhase 1
    Registry statusCompleted

  • A Study of the Cardiac Effects of Danicopan in Healthy Adults

    NCT05016206 · start 2018-07-26

    Registered record
    Registry ID
    NCT05016206
    Conditions
    Healthy
    Interventions
    Danicopan; Moxifloxacin-matching Placebo; Danicopan-matching placebo; Moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-07-26
    Completion
    2018-10-12
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDanicopan; Moxifloxacin-matching Placebo; Danicopan-matching placebo; Moxifloxacin
    PhasePhase 1
    Registry statusCompleted